Effect of teprenone on portal hypertensive gastric mucosa

Digestion

Volumn 57, Issue 1, 1996, Pages 35-40

  Tanoue, Kazuo ^a   Tarnawski, Andrzej S ^b,c   Kishihara, Fumiaki ^a   Ohta, Masayuki ^a   Hashizume, Makoto ^a   Sugimachi, Keizo ^a   Sarfeh, James ^b,c  

^a KYUSHU UNIVERSITY   (Japan)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gastric mucosal blood flow; Geranylgeranylacetone (teprenone); Hexosamine; Portal hypertensive gastropathy; Teprenone

Indexed keywords

HEXOSAMINE; PROSTAGLANDIN; TEPRENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GASTRITIS; INTRAPERITONEAL DRUG ADMINISTRATION; LASER DOPPLER FLOWMETRY; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; STOMACH BLOOD FLOW; STOMACH MUCOSA; STOMACH PH; STOMACH ULCER;

ANIMALS; ANTI-ULCER AGENTS; BLOOD FLOW VELOCITY; DITERPENES; GASTRIC MUCOSA; HEXOSAMINES; HYDROGEN-ION CONCENTRATION; HYPERTENSION, PORTAL; LASER-DOPPLER FLOWMETRY; MALE; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030048814     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201310     Document Type: Article

References (45)

1. Tamawski A, Erickson RA: Sucralfate - 24 years later: Current concepts of its protective and therapeutic action, Eur J Gastroenterol Hepatol 1991;3:795-810.
2. Sarfeh IJ, Tamawski A, Malki A, Mason GR, Ivey KJ: Portal hypertension and gastric mucosal injury in rats: Effects of alcohol, Gastroenterology! 983:84:987-993.
3. Sarfeh U, Tamawski A, Maeda R, Raymont K, Mason GR, Ivey KJ: The gastric mucosa in portal hypertension: Effects of topical bile and acid, Scand J Gastroenterol 1984:19:189-194.
4. Sarfeh I J, Tamawski AI, lajduczek A, Stachura J, Bui HX, Krause WJ: The portal hypertensive gastric mucosa: Histologic, ultrastructural and functional analysis following aspirin-induced damage, Surgery 1988;104:79-85.
5. Tamawski A, Sarfeh IJ, Stachura JI, lajduczek A, Bui HX, Dabros W, Gergelv H: Microvascu-lar abnormalities of the portal hypertensive gastric mucosa, Hepatologv 1988:8:1488-1494.
6. Sarfeh IJ, Soliman H, Waxman K, Coccia M, Rypins EB, Bui HX, Tamawski A: Impaired oxygenation of gastric mucosa in portal hypertension: Hie basis for increased susceptibility to injury, Dig Dis Sci 1989;34:225-228.
7. Arakawa T, Satoh H, Fukuda T, Nakamura H, Kobavashi K: Endogenous prostaglandin E; in gastric mucosa of patients with alcoholic cirrhosis and portal hypertension, Gastroenterology 1987;93:135-140.
8. Arakawa T, Tamawski A, Mach T, Kobavashi K, Sarfeh IJ: Impaired generation of prostaglandins from isolated gastric surface epithelial cells in portal hypertensive rats, Prostaglandins 1990:40:373-382.
9. Arakawa T, Tamawski A, Mach T, Fukuda T, Stachura J, Sarfeh IJ, Kobavashi K: Increased susceptibility to injury and normal reactivity to prostaglandin protection of mucous cells isolated from gastric mucosa of portal hypertensive rats, Prostaglandins 1993:46:397-405.
10. Weiler H, Weiler C, Gerok W: Gastric mucosal prostaglandin E; levels in cirrhosis and portal hypertension, J Hepatol 1990:11:58-64.
11. Yoshimura K, Kraus ER, Shimakura S, Schci-man JM, Boland CR: Role of prostaglandin Ej in cholinergic-medialed glycoprotein synthesis in canine antrum, Dig Dis Sci 1992:37:1045- 1050.
12. Tamawski A, Ivey KJ, Stachura J, Mach T, Klimczyk B, Terano A: Protection by prostaglandin against ethanol-induced gastric mucosal damage in man, An endoscopic and histologic assessment (abstract), Gastroenterology 1981:80:1300.
13. Tamawski A, Stachura J, Ivey KJ, Mach T, Klimczyk B: Ethanol-induced duodenal lesions in man: Protective effect of prostaglandin, Prostaglandins 1981:21:147-153.
14. Tamawski A, Hollander D, Stachura J, Krause WJ, Gergelv H: Prostaglandin protection of the gastric mucosa against alcohol injury: A dynamic time-related process, Gastroenterology 1985;88:334-352.
15. Lacy ER, Ito S: Microscopic analysis of ethanol damage to rat gastric mucosa after treatment with a prostaglandin, Gastroenterology 1982: 83:619-625.
16. Guih PH, Paulsen G, Nagata H: Histologic and microcirculatorv changes in alcohol-induced gastric lesions in the rat: Effect of prostaglandin cytoprotection, Gastroenterology 1984:87: 1083-1090.
17. Hashizume M, Inokuchi K, Tanaka K: The role of prostacyclin in patients with portal hypertension, liver 1985:5:89-93.
18. Kunisaki C, Sugiyama M: Effect of teprenone on acute gastric mucosal lesions induced by cold-restraint stress, Digestion 1992;53:45-53.
19. Murakami M, Oketani K, Fujisaki H, Waka-bayashi T, Ohgo T: Antiulcer effect of geranyl-geranylacetone, a new acyclic polyisoprenoid, on experimentally induced gastric and duodenal ulcers in rats, Arzneimittelforschung 1981: 31:799-804.
20. Terano A, Shiga J, Hiraishi H, Ota S, Sugimoto T: Protective action of tetraprcnylacetone against ethanol-induced damage in rat gastric mucosa, Digestion 1986;35:182-188.
21. Iloh Y, Suzuki K, Matsubara M, Takeyama N, Kitazawa Y, Tanaka T: Changes in gastric mucosal content of adenosine, xanthine and hypo-xanthine induced by restrained water immersion stress: Antiulcer effects of tetraprenylace-tone, Digestion 1991;48:25-33.
22. Nishizawa Y, Sakurai II, Oketani K, Horie T, Yamato C, Moriga M: Effects of taurocholic acid/HCI alone or after pretreatment with gera-nylgeranylacetone on phospholipid metabolism in rat gastric mucosa, Biochem Pharmacol 1987;36:4111-4117.
23. Bilski J, Murty VLN, Nadzicjko C, Sarosiek J, Aono M, Moriga M, Slomianv A, Slomiany BE: Protection against alcohol-induced gastric mucosal injury by geranylgeranylacetone: Effect of indomethacin, Digestion 1988:41:22-33.
24. Hiraishi H, Terano A, Ola S, Mutoh II, Sugimoto T, Harada T, Razandi M, Ivey KJ: Role of mucous glycoprotein in protecting cultured rat gastric mucosal cells against toxic oxygen metabolites, J Lab Clin Med 1993:121:570-578.
25. Arakawa T, Yantada II, Nakamura A, Nebiki H, FukudaT, Nakamura 11. Kobavashi K: Gastric cytoprotection by letraprenylacetone in human subjects, Digestion 1988:39:111-117.
26. Terano A, Hiraishi II, Ota S, Sugimoto T: Gcr-nnylgeranylacctone, a novel anti-ulcer drug, stimulates mucus synthesis and secretion in rat gastric cultured cells, Digestion 1986:33:206-210.
27. Nakazawa S, Tsuboi Y, Tsukamoto J, Yoshino J, Okada M: Serum and stomach tissue levels of geranylgeranylacetone in patients, hit. J Clin Pharmacol Ther Toxicol 1983:21:267-270.
28. Goto Y, Debas HT: Geranylgeranylacetone, a new asystolic polyisoprenoid antiulcer agent (abstract), Gastroenterology 1984:86:1094.
29. Pappas TN, Goto Y, Melendes RE, Garcia R, Debes HT: Tetraprenylacetone (TPA): A new ulcer drug which stimulates bicarbonate production (abstract), Gastroenterology 1986:90: 1578.
30. Kurihara T, Akimoto M, Kurokawa K, Ishigu-ro H, Nimi A, Maeda A, Shigemoto M, Yama-shita K, Yokoyama I: Effects of a gastric mucosal protecting agent in rats with liver cirrhosis, J Gastroenterol Hepatol 1992:7:405-410.
31. Tanoue K, Kitano S, Hashizume M, Wada II, Sugimachi K: A rat model of esophageal varices, Hepaiology 1991;13:353-358.
32. Neuhaus OW, Letzring M: Determination of hexosamines in conjunction with electrophoresis on starch, Anal Chem 1957;29:1230-1233.
33. Groszmann RJ, Colombato LA: Gastric vascular changes in portal hypertension, Hepatology 1988;8:1708-1710.
34. Thiruvengadam R, Gostout CJ: Gastroentero-pathy: An extension of nonvariceal upper gastrointestinal bleeding in portal hypertension, Gastrointest Endosc 1989:35:504-507.
35. Sarfeh IJ, Juler GL, Stemmcr EA, Mason GR: Results of surgical management of hemorrhagic gastritis in patients with gastroesophageal varices, Surg Gynecol Obstet 1982:155:167-170.
36. Babb RR, Mitchell RE: Persistent hemorrhagic gastritis in a patient with portal hypertension and esophagogastric varices: The role of portal decompressive surgery, Am J Gastroenterol 1988:83:777-779.
37. Eebrcc D, Poynard T, Iilion P, Benhamou JP: Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis, N Engl J Med 1981;305:1371-1374.
38. Ilosking SW, Kennedy HE, Seddon I, Trigger DR: The role of propranolol in congestive gas-tropathy of portal hypertension, Hepatology 1987:7:437-441.
39. Kitano S, Koyanagi N, Sugimachi K, Kobaya-shi M, Inokuchi K: Mucosal blood flow and modified vascular responses to norepinephrine in the stomach of rats with liver cirrhosis, Eur Surg Res 1982;14:221-230.
40. Vorobioff J, Bredfeldt JE, Groszmann RJ: Hyperdynamic circulation in portal-hypertensive rat model: A primary factor for maintenance of chronic portal hypertension, Am J Physiol I983:244:G52-G57.
41. Benoit JN, Granger DN: Splanchnic hemodynamics in chronic portal venous hypertension, Semin Liver Dis 1986;6:287-298.
42. Pique JM, Leung FW, Kitahora T, Sarfeh IJ, Tarnawski A, Guth PH: Gastric mucosal blood flow and acid secretion in portal hypertensive rats, Gastroenterology 1988:95:727-733.
43. Pizcueta MP, lacy AM, Kravez, D, Bosch J, Rodés J: Propranolol decreases portal pressure without changing porto-collateral resistance in cirrhotic rats, Hepatology 1989:10:953-958.
44. Piqué JM, Pizcueta MP, Pérez RM, Bosch J: Effects of propranolol on gastric mucosal blood flow and acid secretion in portal hypertensive rats, Hepatology 1990;12:476-480.
45. Ichikawa Y, Tarnawski A, Sarfeh IJ, Ichikawa T, Shintada II: Distorted microangioarchitec-ture and impaired angiogenesis in gastric mucosa of portal hypertensive rats, Gastroenterology 1994:106:702-708.